(Q44797395)

6 December 2017

title

A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis (English)

1 reference

6 December 2017

1 reference

Sunanda Kane

1

1 reference

6 December 2017

Dezheng Huo

series ordinal

2

1 reference

6 December 2017

Kalyani Magnanti

series ordinal

3

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

Clinical Gastroenterology and Hepatology

6 December 2017

published in

1 reference

6 December 2017

volume

1

1 reference

6 December 2017

issue

3

1 reference

6 December 2017

page(s)

170-173

1 reference

Cigarette smoking and ulcerative colitis: a case-control study.

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

Effects of smoking on the presentation and clinical course of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

Increasing patient adherence to gastroenterology treatment and prevention regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

Studies on the mechanism of bowel disturbance in ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

Gastrointestinal motility in patients with ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

A general method of compliance assessment using centralized pharmacy records. Description and validation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

A simple index of Crohn's-disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2970032-9

7 January 2021

10.1016/S1542-3565(03)70032-9

Identifiers

DOI

1 reference

6 December 2017

1 reference